BioInvent International AB: Interim Report January-March 2024

PRESS RELEASE
Published April 24, 2024

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV)

"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs." - Martin Welschof, CEO of BioInvent.

EVENTS IN THE FIRST QUARTER

  • (R) CASI Pharmaceuticals reported positive interim Phase 1 data for BI-1206 in NHL in China
  • Supply agreement signed with AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence® (acalabrutinib)
  • BioInvent regained the rights to immuno-oncology targets from Exelixis

EVENTS AFTER THE END OF THE PERIOD

  • New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)

(R)= Regulatory event

FINANCIAL INFORMATION
First quarter 2024

  • Net sales, SEK 5.9 (16.2) million
  • Profit/loss after tax, SEK -77.9 (-73.7) million
  • Profit/loss after tax per share before and after dilution, SEK -1.18 (-1.12)
  • Cash flow from operating activities, SEK -65.9 (-78.9) million
  • Liquid funds, current and long-term investments at the end of the period, SEK 1,219.2 (1,546.4) million

The complete interim report is available for download below and on the company's website www.bioinvent.com/investors/#financialreports.

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.

For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

Attachments

BioInvent Q1, 2024 EN Final

SOURCE: BioInvent International



View the original press release on accesswire.com

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.